Method: Polysomnography (PSG) was detected overnight, and blood samples were collected at 4 h intervals over 24 h from 13 male healthy controls and 13 male MDD patients before and after treatment with escitalopram for 8 weeks. Objective: To clarify the effects of escitalopram on sleep EEG power in patients with Major depressive disorder (MDD). 9Department of Pharmacology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.8Peking-Tsinghua Center for Life Sciences and PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, China.7Beijing United Family Hospital, Beijing, China.6School of Automation, Hangzhou Dianzi University, Hangzhou, China.5Peking University Health Science Center, Beijing, China.4Key Laboratory of Molecular Cardiovascular Sciences, Peking University, Ministry of Education, Beijing, China.3Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, Beijing, China.2National Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China.1NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Peking University Institute of Mental Health, Peking University Sixth Hospital, Beijing, China.In the interim, from a clinical perspective, escitalopram appears to be beneficial for the treatment of sleep problems in MDD and GAD.Xue-Qin Wang 1, De-Quan Wang 2, Yan-Ping Bao 2, Jia-Jia Liu 1, Jie Chen 1, Shao-Wei Wu 3,4, Hsuan-Nu Luk 5, Ling Yu 1, Wei Sun 1, Yong Yang 6 *, Xue-Hua Wang 7, Lin Lu 1,2,8, Jia-Hui Deng 1 * and Su-Xia Li 2,9 * In MDD, the rate of insomnia as an adverse event after escitalopram was higher than placebo, similar to SSRIs, and lower than SNRIs.Īdditional research assessing the comparative effects of antidepressants with polysomnography is needed. The same pattern was seen for the large proportion (67%-82%) of GAD patients reporting sleep problems at baseline (baseline HAM-A item 4 score ≥ 2). For patients with GAD (n = 2052) the treatment difference in sleep symptoms measured by HAM-A item 4 ("insomnia") was significantly in favor of escitalopram versus placebo (LOCF and MMRM ), but not different to paroxetine or venlafaxine. Sleep-related treatment-emergent adverse events were also compared across groups.įor patients with MDD (n = 5133), the treatment difference on MADRS item 4 ("reduced sleep") was significantly in favor of escitalopram versus placebo (LOCF and MMRM ), versus SSRIs (LOCF and MMRM ). Both last observation carried forward (LOCF) and repeated measurements (MMRM) were used to analyze the sleep item of the Montgomery Åsberg Depression Rating Scale (MADRS) or Hamilton Anxiety Rating Scale (HAM-A) after 8 weeks of treatment. First-line antidepressants, including the selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRIs), may have different effects on sleep.ĭata from 22 randomized, controlled trials comparing escitalopram with SSRIs, SNRIs, or placebo in the treatment of adult MDD or GAD were included. Disturbed sleep is a key symptom in major depressive disorder (MDD) and generalized anxiety disorder (GAD).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |